Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2011 Aug 1.

Published in final edited form as: Lung Cancer. 2009 Nov 28;69(2):172–179. doi: 10.1016/j.lungcan.2009.11.002

Table 3. Promoter hypermethylation in NSCLC tissues, by histologic type.

	Histology
	All Adenocarcinoma		Squamous (n=39)	Large Cell (n=20)	Mixed, NOS, or Other (n=7)
	Non-BAC (n=43)	BAC (n=8)	Squamous (n=39)	Large Cell (n=20)	Mixed, NOS, or Other (n=7)
APC^*	19 (45%)	6 (75%)	6 (17%)	10 (53%)	2 (29%)
BVES	8 (19%)	3 (38%)	7 (18%)	6 (30%)	3 (43%)
CCND2^*	19 (45%)	4 (50%)	1 (3%)	8 (42%)	1 (14%)
CDH1	3 (7%)	0 (0%)	2 (5%)	0 (0%)	2 (29%)
CDH13	5 (12%)	1 (13%)	4 (10%)	2 (10%)	1 (14%)
CDKN2A	6 (14%)	0 (0%)	18 (46%)	5 (25%)	1 (14%)
DAPK1	2 (5%)	0 (0%)	5 (13%)	0 (0%)	0 (0%)
KCNH5	11 (26%)	3 (38%)	0 (0%)	6 (30%)	2 (29%)
KCNH8	5 (12%)	1 (13%)	0 (0%)	6 (30%)	0 (0%)
MGMT	0 (0%)	0 (0%)	4 (10%)	1 (5%)	0 (0%)
OPCML	7 (16%)	1 (13%)	0 (0%)	5 (25%)	3 (43%)
RARB	14 (33%)	2 (25%)	12 (31%)	7 (35%)	1 (14%)
RASSF1	14 (33%)	2 (25%)	7 (18%)	9 (45%)	3 (43%)
RUNX	14 (33%)	2 (25%)	1 (3%)	6 (30%)	2 (29%)
TMS1	7 (16%)	0 (0%)	2 (5%)	0 (0%)	0 (0%)

^*

Only had 42 Non-BAC, 36 Squamous, and 19 Large Cell tissue samples sufficient for methylation analysis